ClinicalTrials.gg
CompletedNCT02421588CORAILUpdated Apr 3, 2020Results posted

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

A Phase 3 interventional study of Lurbinectedin (PM01183) and Pegylated liposomal doxorubicin (PLD) in Ovarian Cancer, sponsored by PharmaMar. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by PharmaMar · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
132nd of 1,498
442 · median 47
Started
2015
with 67 others
Phase 3
103 of 1,779
18 open now
Registered
885th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 132nd largest by enrollment of the 1,498 interventional ones that give a count, is one of 68 that started in 2015, is one of 103 in phase 3, and was the 885th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 18 years
  • Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.
  • Platinum-resistant disease (PFI: 1-6 months after last platinum-containing chemotherapy).
  • Evaluable disease according to (RECIST) v.1.1 criteria
  • No more than three prior systemic chemotherapy regimens
  • (ECOG) performance status (PS) (ECOG PS) ≤ 2
  • Adequate hematological, renal, metabolic and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major illness
  • Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.
  • Requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
442 participants (actual)

Study arms

  • Experimental
    Arm A

    lurbinectedin (PM01183)

    Drug: Lurbinectedin (PM01183)

  • Active comparator
    Arm B

    pegylated liposomal doxorubicin OR topotecan

    Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Topotecan

06

What researchers measure

Primary outcomes

  1. Progression-free Survival by Independent Review Committee

    The primary endpoint was PFS by IRC assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.

    Time frame: Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years

Secondary outcomes

  1. Progression-free Survival by Investigator's Assessment

    The primary endpoint was PFS by Investigator's Assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.

    Time frame: Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years

  2. Overall Survival (OS)

    Calculated from the date of randomization to the date of death (death event) or last contact (in this case, survival was censored on that date).

    Time frame: From the date of randomization to the date of death or last contact, up to 12 months after last patient inclusion, for a maximum of up to 3 years

  3. Overall Response Rate (ORR) by Independent Review Committee

    Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.

    Time frame: At baseline and every eight weeks from randomization until evidence of PD, assessed up to 3 years

  4. Overall Response Rate by Investigator's Assessment

    Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.

    Time frame: At baseline and every eight weeks from randomization until evidence of PD, assessed up to 3 years

  5. Duration of Response by Independent Review Committee

    Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.

    Time frame: The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years

  6. Duration of Response by Investigator's Assessment

    Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.

    Time frame: The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years

  7. Best Response According to Tumor Marker Evaluation (CA-125)

    Best response according to tumor marker evaluation (CA-125): defined as the best response obtained according to GCIG criteria. Tumor marker assessments were performed at baseline and every eight weeks from randomization until evidence of PD. Progression based on serum CA-125 levels was defined on the basis of a progressive serial elevation of serum CA-125 according to: A. Patients with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart or B. Patients with elevated CA-125 before treatment, which never normalizes, must show evidence of CA-125 greater than, or equal to, 2 times the nadir value on 2 occasions at least 1 week apart or C. Patients with CA-125 in the reference range before treatment must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart.

    Time frame: At baseline and every eight weeks from randomization until evidence of PD, up to 3 years

07

Results

Posted Mar 5, 2020

Participant flow

First randomization/first study treatment administration took place on 26JUN2015. The cutoff date for results was 12OCT2018. 534 patients were screened; 442 were randomized at 83 sites/12 countries. 10 patients did not receive the study treatment.

Participant flow — Overall Study
MilestoneLurbinectedinControl (PLD or Topotecan)
Started221221
Completed00
Not completed221221
Withdrew: Non-treatment-related ae88
Withdrew: Progressive disease152135
Withdrew: Death113
Withdrew: Physician decision817
Withdrew: Other reason not specified31
Withdrew: Symptomatic deterioration1319
Withdrew: Treatment-related ae1014
Withdrew: Withdrawal by subject1416
Withdrew: Not treated28

Outcome measures

PrimaryProgression-free Survival by Independent Review Committee

The primary endpoint was PFS by IRC assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.

Time frame:
Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years
Reported as:
Median · months
Progression-free Survival by Independent Review Committee
monthsLurbinectedinControl (PLD or Topotecan)
Progression-free Survival by Independent Review Committee3.5 (2.1 to 3.7)3.6 (2.7 to 3.8)
Statistical analysis
  • Lurbinectedin vs Control (PLD or Topotecan) · Log Rank · p = 0.6294 · Hazard ratio (hr): 1.057 · 95% CI 0.854 to 1.309
  • Lurbinectedin · Pfs at 6 months: 24.3 · 95% CI 18.4 to 30.7Percent of Participants
  • Control (PLD or Topotecan) · Pfs at 6 months: 27.5 · 95% CI 20.9 to 34.4Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Normal approximation · p = 0.5032
  • Lurbinectedin · Pfs at 12 months: 8.3 · 95% CI 4.7 to 13.3Percent of Participants
  • Control (PLD or Topotecan) · Pfs at 12 months: 7.0 · 95% CI 3.3 to 12.5Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Normal approximation · p = 0.6742
SecondaryProgression-free Survival by Investigator's Assessment

The primary endpoint was PFS by Investigator's Assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.

Time frame:
Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years
Reported as:
Median · months
Progression-free Survival by Investigator's Assessment
monthsLurbinectedinControl (PLD or Topotecan)
Progression-free Survival by Investigator's Assessment3.7 (3.6 to 3.9)3.7 (3.5 to 4.0)
Statistical analysis
  • Lurbinectedin vs Control (PLD or Topotecan) · Log Rank · p = 0.7673 · Hazard ratio (hr): 0.987 · 95% CI 0.805 to 1.209
  • Lurbinectedin · Pfs at 6 months: 29.0 · 95% CI 22.8 to 35.4Percent of Participants
  • Control (PLD or Topotecan) · Pfs at 6 months: 27.4 · 95% CI 21.3 to 33.9Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Normal approximation · p = 0.7385
  • Lurbinectedin · Pfs (%) at 12 months: 8.2 · 95% CI 4.8 to 12.7Percent of Participants
  • Control (PLD or Topotecan) · Pfs (%) at 12 months: 7.5 · 95% CI 4.2 to 12.2Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Normal approximation · p = 0.8245
SecondaryOverall Survival (OS)

Calculated from the date of randomization to the date of death (death event) or last contact (in this case, survival was censored on that date).

Time frame:
From the date of randomization to the date of death or last contact, up to 12 months after last patient inclusion, for a maximum of up to 3 years
Reported as:
Median · months
Overall Survival (OS)
monthsLurbinectedinControl (PLD or Topotecan)
Overall Survival (OS)11.4 (9.0 to 14.2)10.9 (9.3 to 12.5)
Statistical analysis
  • Lurbinectedin vs Control (PLD or Topotecan) · Log Rank · p = 0.8021 · Hazard ratio (hr): 0.956 · 95% CI 0.772 to 1.183
  • Lurbinectedin · Os at 12 months: 48.2 · 95% CI 41.3 to 54.8Percent of Participants
  • Control (PLD or Topotecan) · Os (%) at 12 months: 45.3 · 95% CI 38.4 to 52.0Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Normal approximation · p = 0.5515
  • Lurbinectedin · Os (%) at 24 months: 22.3 · 95% CI 16.8 to 28.2Percent of Participants
  • Control (PLD or Topotecan) · Os (%) at 24 months: 22.7 · 95% CI 17.1 to 28.7Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Normal approximation · p = 0.9253
SecondaryOverall Response Rate (ORR) by Independent Review Committee

Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.

Time frame:
At baseline and every eight weeks from randomization until evidence of PD, assessed up to 3 years
Reported as:
Count of participants · Participants
Overall Response Rate (ORR) by Independent Review Committee
ParticipantsLurbinectedinControl (PLD or Topotecan)
Complete response33
Partial response2925
Stable disease9097
Progressive disease8372
Unknown1624
Statistical analysis
  • Lurbinectedin · Orr: 14.5 · 95% CI 10.1 to 19.8Percent of Participants
  • Control (PLD or Topotecan) · Orr: 12.7 · 95% CI 8.6 to 17.8Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Fisher Exact · p = 0.6772
SecondaryOverall Response Rate by Investigator's Assessment

Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.

Time frame:
At baseline and every eight weeks from randomization until evidence of PD, assessed up to 3 years
Reported as:
Count of participants · Participants
Overall Response Rate by Investigator's Assessment
ParticipantsLurbinectedinControl (PLD or Topotecan)
Complete response32
Partial response3235
Stable disease10794
Progressive disease6368
Unknown1622
Statistical analysis
  • Lurbinectedin · Orr: 15.8 · 95% CI 11.3 to 21.3Percent of Participants
  • Control (PLD or Topotecan) · Overall response rate (orr): 16.7 · 95% CI 12.1 to 22.3Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Fisher Exact · p = 0.8976
SecondaryDuration of Response by Independent Review Committee

Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.

Time frame:
The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years
Reported as:
Median · months
Duration of Response by Independent Review Committee
monthsLurbinectedinControl (PLD or Topotecan)
Duration of Response by Independent Review Committee4.0 (1.9 to 5.7)3.7 (3.6 to 7.2)
Statistical analysis
  • Lurbinectedin vs Control (PLD or Topotecan) · Log Rank · p = 0.2631 · Hazard ratio (hr): 1.406 · 95% CI 0.769 to 2.569
SecondaryDuration of Response by Investigator's Assessment

Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.

Time frame:
The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years
Reported as:
Median · months
Duration of Response by Investigator's Assessment
monthsLurbinectedinControl (PLD or Topotecan)
Duration of Response by Investigator's Assessment4.3 (3.6 to 5.8)3.7 (3.2 to 5.6)
Statistical analysis
  • Lurbinectedin vs Control (PLD or Topotecan) · Log Rank · p = 0.8276 · Hazard ratio (hr): 1.056 · 95% CI 0.64 to 1.743
SecondaryBest Response According to Tumor Marker Evaluation (CA-125)

Best response according to tumor marker evaluation (CA-125): defined as the best response obtained according to GCIG criteria. Tumor marker assessments were performed at baseline and every eight weeks from randomization until evidence of PD. Progression based on serum CA-125 levels was defined on the basis of a progressive serial elevation of serum CA-125 according to: A. Patients with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart or B. Patients with elevated CA-125 before treatment, which never normalizes, must show evidence of CA-125 greater than, or equal to, 2 times the nadir value on 2 occasions at least 1 week apart or C. Patients with CA-125 in the reference range before treatment must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart.

Time frame:
At baseline and every eight weeks from randomization until evidence of PD, up to 3 years
Reported as:
Count of participants · Participants
Best Response According to Tumor Marker Evaluation (CA-125)
ParticipantsLurbinectedinControl (PLD or Topotecan)
Complete response133
Partial response3329
Stable disease9594
Progressive disease1716
Unknown1523
Statistical analysis
  • Lurbinectedin · Orr (%): 26.6 · 95% CI 20.2 to 33.8Percent of Participants
  • Control (PLD or Topotecan) · Orr (%): 19.4 · 95% CI 13.7 to 26.3Percent of Participants
  • Lurbinectedin vs Control (PLD or Topotecan) · Fisher Exact · p = 0.1231

Adverse events

Collected over Participants were assessed through study completion, approximately 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurbinectedin170/219 (77.6%)92/219 (42%)212/219 (96.8%)
Control (PLD or Topotecan)171/213 (80.3%)85/213 (39.9%)211/213 (99.1%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventLurbinectedinControl (PLD or Topotecan)
Intestinal obstructionGastrointestinal disorders24/21921/213
Febrile neutropeniaBlood and lymphatic system disorders14/21912/213
NeutropeniaBlood and lymphatic system disorders11/21913/213
AnaemiaBlood and lymphatic system disorders8/21912/213
ThrombocytopeniaBlood and lymphatic system disorders9/21911/213
VomitingGastrointestinal disorders10/2194/213
AscitesGastrointestinal disorders4/2197/213
NauseaGastrointestinal disorders7/2194/213
Abdominal painGastrointestinal disorders6/2196/213
SepsisInfections and infestations5/2191/213
Most frequent other events
Showing 10 of 32
Most frequent other events
EventLurbinectedinControl (PLD or Topotecan)
NauseaGastrointestinal disorders156/21992/213
FatigueGeneral disorders133/219113/213
NeutropeniaBlood and lymphatic system disorders73/21989/213
VomitingGastrointestinal disorders87/21958/213
AnaemiaBlood and lymphatic system disorders57/21977/213
Abdominal painGastrointestinal disorders74/21952/213
ConstipationGastrointestinal disorders72/21961/213
Mucosal inflammationGeneral disorders22/21968/213
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders3/21951/213
Decreased appetiteMetabolism and nutrition disorders51/21947/213

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LurbinectedinControl (PLD or Topotecan)Total
<=18 years000
Between 18 and 65 years126141267
>=65 years9580175
Age, Continuous
Age, Continuous(years)LurbinectedinControl (PLD or Topotecan)Total
Median63.0 (25 to 85)59.0 (28 to 87)61.0 (25 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)LurbinectedinControl (PLD or Topotecan)Total
Female221221442
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LurbinectedinControl (PLD or Topotecan)Total
American Indian or Alaska Native011
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American628
White192201393
More than one race000
Unknown or Not Reported211435
Region of Enrollment
Region of Enrollment(participants)LurbinectedinControl (PLD or Topotecan)Total
United States394079
Romania111122
Spain404686
United Kingdom171431
Austria347
Belgium211940
Bulgaria5510
Czechia5510
France191231
Hungary91423
Italy474794
Serbia549
Body mass index
Body mass index(Participants)LurbinectedinControl (PLD or Topotecan)Total
≤20 kg/m^2263763
20-25 kg/m^28284166
25-30 kg/m^26251113
>30 kg/m^2504999
Unknown101
ECOG PS
ECOG PS(Participants)LurbinectedinControl (PLD or Topotecan)Total
PS 0126123249
PS 18794181
PS 28412
Primary site
Primary site(Participants)LurbinectedinControl (PLD or Topotecan)Total
Ovarian196195391
Fallopian111324
Peritoneal141327

15 further baseline measures are reported on the registry.

08

Study locations

28 sites
  • 1112
    Peoria, Arizona, United States
  • 1102
    Greenbrae, California, United States
  • 1103
    La Jolla, California, United States
  • 1116
    Los Angeles, California, United States
  • 1120
    Los Angeles, California, United States
  • 1113
    Palo Alto, California, United States
  • 1111
    San Francisco, California, United States
  • 1122
    Santa Maria, California, United States
  • 1123
    West Hills, California, United States
  • 1109
    Augusta, Georgia, United States
  • 1104
    Indianapolis, Indiana, United States
  • 1110
    Covington, Louisiana, United States
  • 1124
    Scarborough, Maine, United States
  • 1121
    Brick, New Jersey, United States
  • 1127
    Albany, New York, United States
  • 1105
    New York, New York, United States
  • 1117
    Asheville, North Carolina, United States
  • 1101
    Charlotte, North Carolina, United States
  • 1125
    Charlotte, North Carolina, United States
  • 1108
    Durham, North Carolina, United States
  • 1107
    Columbus, Ohio, United States
  • 1118
    Dayton, Ohio, United States
  • 1119
    Pittsburgh, Pennsylvania, United States
  • 1115
    Greenville, South Carolina, United States
  • 1129
    Nashville, Tennessee, United States
  • 1131
    Fort Worth, Texas, United States
  • 1128
    Houston, Texas, United States
  • 1106
    Charlottesville, Virginia, United States
09

References and documents

Publications

  • Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021 Nov;163(2):237-245. doi: 10.1016/j.ygyno.2021.08.032. Epub 2021 Sep 11. PubMed 34521554 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Oct 2018 and a completion of Oct 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2020, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2015
First posted
Apr 20, 2015
Start
May 2015
Primary completionActual
Oct 12, 2018
CompletionActual
Oct 12, 2018
Results first posted
Mar 5, 2020
Last update
Apr 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02421588
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Apr 20, 2015
Start date
May 2015
Primary completion
Oct 12, 2018
Completion
Oct 12, 2018
Results posted
Mar 5, 2020
Last update
Apr 3, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion